Radically altering drug discovery, designing globally important therapeutics

We design peptides with purpose – for globally important therapeutic applications

supt/page-header

Page Header

Unlocking novel chemical space to address challenging drug targets

supt/text-media

Text & Image

Our computational drug design platform connects and extracts insights from diverse biomedical data, allowing us to unlock a new universe of unexplored, novel peptides with powerful applications.

Introduce your section or article with a short text.

We generate novel compounds with an end-product and use in mind, focused toward unexplored intellectual property.

supt/introduction

Introduction

Discover our platform

supt/button

Button

Backed by leading life science &amp; technology investors

supt/section-partners

Partners

supt/list-partners

List of Partners

supt/card-partner

Card Partner

Europe and US-based life science &amp; technology fund

Leading international technology investment fund

Encourage your visitor to visit another page, to further understand/engage.

supt/section-ctas

Call-to-Actions

supt/list-ctas

List of Call-to-Actions

We enable novel peptide design, optimization and manufacturing across disease areas.

Platform Partnering

Partnering

supt/card-cta

Card Call-to-Action

Our internal, clinical-stage pipeline focuses solely on novel, highly potent, narrow and broad-spectrum anti-infectives for unmet needs.

Internal Assets

Pipeline

Latest news

See all news

supt/section-news

Latest News

Peptilogics Announces Two Peer-Reviewed Publications on Designed Peptide Therapeutic PLG0206 for Periprosthetic Joint Infection

Peptilogics Presents Positive First-in-Human Phase 1 Data for its Lead Engineered Antibacterial Peptide, PLG0206, at IDWeek 2021

Peptilogics to Present First-in-Human Phase 1 Clinical Data of PLG0206 at IDWeek 2021

Are you interested in working with Peptilogics on peptide drug discovery &amp; development?